Novo Nordisk's New Weight-Loss Drugs Show Groundbreaking Trial Results

Novo Nordisk's New Weight-Loss Drugs Show Groundbreaking Trial Results

Is Novo Nordisk (NVO) Stock Finally Turning a Corner With Amycretin Weight-Loss Drug?

Novo Nordisk's New Weight-Loss Drugs Show Groundbreaking Trial Results

Novo Nordisk has unveiled promising results from trials of its weight-loss and diabetes drugs, including semaglutide and a new experimental treatment called amycretin. The company’s latest data highlights significant benefits in weight reduction, heart health, and inflammation control. Yet, despite these advances, its stock has fallen sharply over the past two years. In a phase 2 trial, amycretin—a single-molecule drug unlike the dual-action CagriSema—delivered up to 14.6% weight loss over 36 weeks. Participants also saw a 1.71 percentage point drop in A1C levels from a baseline of 7.8%. Novo Nordisk now plans to develop both injectable and oral versions of the treatment, which could simplify production and improve effectiveness.

Separate studies on semaglutide showed broad health improvements. Patients with uncontrolled high blood pressure experienced a 5.48 mmHg greater reduction in systolic pressure compared to placebo. Those with obesity, asthma, and heart disease reported fewer asthma-related complications. Liver health data from the ESSENCE trial also revealed steady improvements in cardiometabolic risk factors and liver function markers over 72 weeks. Further findings indicated a 52% lower incidence of obstructive sleep apnea (OSA) in patients using semaglutide 2.4 mg. Among participants without OSA at the start, only 30 developed the condition on semaglutide, versus 65 on placebo. Inflammation levels also dropped, with a 38.9% reduction in hsCRP, a key marker for systemic inflammation.

The results position amycretin and semaglutide as powerful tools for weight management and metabolic health. Novo Nordisk’s pipeline continues to expand, though its stock has declined by roughly 68% in the last two years. The company now moves forward with plans to bring amycretin to market in multiple forms.

Neueste Nachrichten